Zymeworks Common Stock Stock Performance
| ZYME Stock | USD 12.72 0.21 1.62% |
The firm maintains a market beta of -0.74, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Zymeworks Common are expected to decrease at a much lower rate. During the bear market, Zymeworks Common is likely to outperform the market. At this point, Zymeworks Common Stock has a negative expected return of -0.12%. Please make sure to check out Zymeworks Common's treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Zymeworks Common Stock performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Zymeworks Common Stock has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's primary indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders. ...more
| Begin Period Cash Flow | 157.6 B |
Zymeworks |
Zymeworks Common Relative Risk vs. Return Landscape
If you would invest 1,414 in Zymeworks Common Stock on December 24, 2024 and sell it today you would lose (142.00) from holding Zymeworks Common Stock or give up 10.04% of portfolio value over 90 days. Zymeworks Common Stock is currently does not generate positive expected returns and assumes 3.2842% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than Zymeworks, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Zymeworks Common Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Zymeworks Common's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Zymeworks Common Stock, and traders can use it to determine the average amount a Zymeworks Common's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0374
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ZYME |
Estimated Market Risk
| 3.28 actual daily | 29 71% of assets are more volatile |
Expected Return
| -0.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Zymeworks Common is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Zymeworks Common by adding Zymeworks Common to a well-diversified portfolio.
Zymeworks Common Fundamentals Growth
Zymeworks Stock prices reflect investors' perceptions of the future prospects and financial health of Zymeworks Common, and Zymeworks Common fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Zymeworks Stock performance.
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (1.61) % | ||||
| Operating Margin | (0.72) % | ||||
| Current Valuation | 677.75 M | ||||
| Shares Outstanding | 69.58 M | ||||
| Price To Earning | (2.36) X | ||||
| Price To Book | 2.61 X | ||||
| Price To Sales | 11.60 X | ||||
| Revenue | 76.3 M | ||||
| EBITDA | (137.11 B) | ||||
| Cash And Equivalents | 241.83 M | ||||
| Cash Per Share | 4.18 X | ||||
| Total Debt | 18.48 B | ||||
| Debt To Equity | 0.14 % | ||||
| Book Value Per Share | 4.91 X | ||||
| Cash Flow From Operations | (110.04 B) | ||||
| Earnings Per Share | (1.62) X | ||||
| Total Asset | 463.09 B | ||||
| Retained Earnings | (830.34 B) | ||||
About Zymeworks Common Performance
By analyzing Zymeworks Common's fundamental ratios, stakeholders can gain valuable insights into Zymeworks Common's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Zymeworks Common has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Zymeworks Common has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada. Zymeworks operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 284 people.Things to note about Zymeworks Common Stock performance evaluation
Checking the ongoing alerts about Zymeworks Common for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Zymeworks Common Stock help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Zymeworks Common generated a negative expected return over the last 90 days | |
| Zymeworks Common has high historical volatility and very poor performance | |
| Zymeworks Common has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 76.3 M. Net Loss for the year was (122.69 B) with loss before overhead, payroll, taxes, and interest of (60.2 M). | |
| Zymeworks Common Stock currently holds about 241.83 M in cash with (110.04 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.18. | |
| Over 100.0% of the company outstanding shares are owned by institutional investors |
- Analyzing Zymeworks Common's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Zymeworks Common's stock is overvalued or undervalued compared to its peers.
- Examining Zymeworks Common's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Zymeworks Common's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Zymeworks Common's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Zymeworks Common's stock. These opinions can provide insight into Zymeworks Common's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Zymeworks Stock analysis
When running Zymeworks Common's price analysis, check to measure Zymeworks Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zymeworks Common is operating at the current time. Most of Zymeworks Common's value examination focuses on studying past and present price action to predict the probability of Zymeworks Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zymeworks Common's price. Additionally, you may evaluate how the addition of Zymeworks Common to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |